Merck Sharp + Dohme Corp.

Mersana Therapeutics, Inc.

Other

Liping Yang

M Arshad Siddiqui

Chaoyang Dai

Francesc Xavier Fradera Llinas

Michelle R Machacek

Matthew Ernst Voss

B Wesley Trotter

Christopher Francis Thompson

Michael Hale Reutershan

Ronald J Doll

Joseph A Kozlowski

Michael D Altman

Christopher J Dinsmore

Timothy B Lowinger

Wensheng Yu

Stephane L Bogen

Janeta Popovici-Muller

Ling Tong

Dansu Li

Manami Shizuka

De-Yi Yang

Neville J Anthony

Maria Emilia Di Francesco

Matthew Christopher

Bandarpalle B Shankar

Brian J Lavey

Umar Faruk Mansoor

Vinay M Girijavallabhan

Michael K C Wong

Seong Heon Kim

Joshua D Thomas

Guowei Zhou

Binyuan Sun

Razia Rizvi

Kristin E Rosner

Eugene W Kelleher

Michelle Martinez

Dorin Toader

Robert Feltz

Judson E Richard

Aneta Maria Kosinski

Luke Fire

Marc I Damelin

Jeremy R Duvall

Keith W Bentley

Angie R Angeles

Naniye Cetinbas

Raghida A Bukhalid

Ling Xu

Joey Lee Methot

Solomon D Kattar

Jason David Katz

Rong Zhang

Abdelghani Achab

Yongqi Deng

Feng Shi

Matthew H Daniels

Lei Chen

Lianyun Zhao

Andrew J McRiner

Latha G Nair

Yaolin Wang

Meredeth Ann McGowan

Zhaoyang Meng

Kin Chiu Fong

Weidong Pan

David Benjamin Belanger

Panduranga Adulla P Reddy

Mehul F Patel

Patrick J Curran

Changwei Mu

Duan Liu

Chaomin Li

Shuyi Tang

Yang Nan

Xiaoli Zhao

Amit K Mandal

Carolyn Michele Cammarano

Yudith Garcia

Dietrich P Steinhuebel

Baijun Ye

Xiaona Wang

Sixing Zhang

Xiansheng Leng

Meredeth A Mcgowan

Lalanthi Dilrukshi Vitharana

Lalalnthi Dilrukshi Vitharana

Amit Ashokro Kudale

Jagannath Panda

Anthappan Tony Kurissery

Matthew E Voss

Raghu Bolisetti

Partha Ghosh

Jaya Prakash Samala

Abdelghani Abe Achab

Matthew P Christopher

Neville John Anthony

Andrew Mcriner

Matthew Hersh Daniels

The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Antibody drug conjugates comprising sting agonists

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7 substituted purines as HDM2 inhibitors

The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Substituted pyrrolopyrimidines as HDM2 inhibitors

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7,8 substituted purines as HDM2 inhibitors

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I 

Compounds for inhibiting KSP kinesin activity

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

Growing community of inventors

Arlington, MA, United States of America

Liping Yang